Study aim: The Co-supplementation of Curcumin and Amla on lipids, Glycemic status, Inflammatory factor, Antioxidant indices, and liver enzymes in Patients with DM2 Design: parallel, double-blind ، randomized. Settings and conduct: Participants with type 2 diabetes are referred to the diabetes clinic of Bushehr University of Medical Sciences, and will be diagnosed by an endocrinologist. they will be divided into two groups of 25 patients receiving Curcumin +Amla and placebo supplementation. patients receiving Curcumin and Amla 2 capsules daily 500 mg (250mg Curcumin +250mg Amla) and patients in the placebo group also take 2 capsules that are similar in appearance to intervention supplements half an hour after the main meal for 12 weeks. Cans containing capsules and how to use them were coded by a non-researcher as allocation concealment for lack of observing the type of received capsule information. Participants/Inclusion and exclusion criteria: Inclusion criteria (1 year history of diabetes, age 25 to 65 , BMI 25 and 34.9, taking blood sugar oral medications, informed consent. Exclusion criteria;, (suffering from chronic diseases (liver, kidney, heart, thyroid, rheumatic, pulmonary, metabolic, digestive, malignancies, allergies) pregnancy, breastfeeding, insulin treatment and... etc.) Intervention groups: Patients are randomly divided into two groups of 25 patients receiving curcumin and Amla and placebo supplementation. In this study, patients are given the supplements for 12 weeks, half an hour after the main meal.. Patients who received 2 capsules of curcumin and Amla (250mg curcumin +250mg Amla) and patients who are in the group receiving placebo (wheat flour) 2capsules daily500 mg, which are similar in appearance to intervention supplements. Main outcome variables: Lipid profile, Glycemic indices, Antioxidant indices, Inflammatory factor, and liver enzymes